Ypsomed Holding AG

Ypsomed Holding AG is a prominent medical technology company specializing in the design, development, and manufacture of injection and infusion systems for self-medication. Celebrating over four decades in business, Ypsomed is recognized as a leading innovator in diabetes care, providing a comprehensive range of solutions for patients requiring regular administration of medications. Its core offerings include autoinjectors, pen injectors, insulin pumps, and infusion sets, serving therapeutic areas such as diabetes, infertility, growth disorders, and other chronic or specialized conditions. Operating under the mylife Diabetescare brand for direct-to-patient and healthcare provider solutions, and Ypsomed Delivery Systems for business-to-business collaborations, Ypsomed partners with major pharmaceutical and biotech companies globally. Headquartered in Burgdorf, Switzerland, the company manages an international network of subsidiaries, production facilities, and distribution partners, reinforcing its status as a pivotal player in advancing self-care and injectable therapy technologies in the healthcare sector.